Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven diagnosis of primary GIST (without peritoneal or distant metastasis) with positive immunostaining for KIT (CD117);
Undergone complete gross resection of a primary GIST within 70 days prior to enrollment (includes R0 \[negative microscopic margins\] and R1 \[positive microscopic margins\]);
Intermediate or high risk of recurrence based on Corless criteria (Section 5.1):
You may not be if
Patient has received prior therapy with imatinib, or any other molecular targeted or biological therapy.
Clareo Health | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)
